Spencer H. Shao

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Medicine, Oncology, Pharmacology +13

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 253 citations · Full text

Medicine, Oncology, Pharmacology +12

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

John H. Strickler, Andrea Cercek, Salvatore Siena et al. · The Lancet Oncology · 2023 · 245 citations · Full text

Medicine, Oncology, Pharmacology +10

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

Nathan Fowler, Felipe Samaniego, Wojciech Jurczak et al. · Journal of Clinical Oncology · 2021 · 161 citations · Full text

Medicine, Oncology, Pharmacology +13

Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

Sheri Skerget, Daniel Peñaherrera, Ajai Chari et al. · Nature Genetics · 2024 · 75 citations · Full text

Medicine, Molecular Genetics, Oncology +17